Article
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Anticancer research - 1 Apr 2014
Iwamoto Shigeyoshi, Hazama Shoichi, Kato Takeshi, Miyake Yasuhiro, Fukunaga Mutsumi, Matsuda Chu, Bando Hiroyuki, Sakamoto Junichi, Oba Koji, Mishima Hideyuki
Abstract excerpt
BACKGROUND: This study was the first multicenter phase II study of cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type mCRC as a second-line treatment in Japan including BRAF and PIK3CA genotyping. PATIENTS AND METHODS: Tumors of 112 pre-registered patients were genotyped for KRAS, BRAF, and PIK3CA. The primary study end-point was response rate, and secondary end-points were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.